Update on the practice of mechanical ventilation in non-ARDS ICU patients - PRoVENT 2⁺

PRoVENT 2⁺ aims to investigate the current worldwide practice of invasive mechanical ventilation as well as risk factors and clinical outcomes of adult ICU patients.

Primary Endpoint:
Proportion of patients ventilated within lung-protective limits, defined as tidal volume of ≤8 ml/kg predicted body weight and positive end-expiratory pressure of ≥5 cmH_2O (both must be met).



Inclusion criteria:
- Patients admitted to intensive care unit within enrolment window;
- Initiation of high-flow nasal oxygen (HFNO, ≥30 l/min) or NIV/CPAP with at least 5 cmH_2O expiratory pressure or invasive mechanical ventilation within enrolment window

Exclusion criteria:
- Age <18 years;
- Patients transferred from another hospital under ongoing invasive or non-invasive ventilation



Study time line and visit schedule:



Study design: Multi-centre prospective observational cohort study
Timing: Enrolment window of 1-4 coherent weeks, which can be individually chosen by study centres depending on their expected patient volume
Planned sample size: ≥1151 patients
Endorsement: PRoVENT 2⁺ is officially supported by the European Society of Anaesthesiology and Intensive Care (ESAIC)

PRoVENT 2⁺ STARTS SOON - JOIN THE STUDY TEAM NOW!

We are recruiting study centres, local and national coordinating investigators, as well as section coordinators for neuro and cardiac intensive care worldwide! Are you interested in taking an active role in PRoVENT 2⁺? Please contact the chief investigator Dr. Martin Scharffenberg via martin.scharffenberg@ukdd.de!
Further information can be found here: https://www.esaic.org/research/research-groups/provent-2/